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Abstract 
Aims:  To determine whether older people are prescribed antidepressants at lower levels of 
depression and with fewer symptoms, and whether they are more likely to engage in chronic 
usage.   
Methods:  An online survey about experiences with, and opinions about, depression and 
antidepressants, was completed by 1,825 New Zealand adults who had been prescribed 
antidepressants in the preceding five years.  
Results:  Participants over 55 were prescribed antidepressants with significantly fewer 
symptoms and were significantly less likely to meet DSM criteria for depression. They were 
also significantly more likely to have used the drugs for three years and still be using them.  
Conclusions:   Prescribing physicians and their older patients might benefit from discussing 
the pros and cons of antidepressants (including the additional risk factors with this age 
group) and the alternatives; and, if prescription does occur, careful monitoring to avoid 
unnecessary, potentially damaging, long-term use is recommended. 
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Introduction 
Although depression is the most common mental health problem [1], general population 
surveys, including in New Zealand – where the current study was conducted, show that older 
people have a lower prevalence of depression, with shorter duration and less severity [2].  
This trend is, however, reversed towards the end of life [2], with a recent meta-analysis 
calculating a prevalence rate of diagnosed ‘depressive disorders’ in people aged >75 of 
17.1% [3]. 
 
Age and prescribing rates of anti-depressants 
Prescribing rates of antidepressants (ADs) are approaching epidemic proportions. In New 
Zealand (where the current study was conducted) the number of people prescribed ADs 
increased 35% from 304,530 to 412,631 between 2006/07 and 2011/12 (PHARMAC, 
personal communication, 2012), meaning that approximately one in nine of the adult 
population receive ADs every year. In 2013 there were 53 million prescriptions in England, a 
country with a population of 52.6 million [4]. These increases in annual prescriptions are less 
explicable in terms of new recipients but are more the result of people staying on ADs for 
longer [5]. 
 
In the Netherlands there was a 5.8 fold increase between 1991 and 2011 in SSRI prescribing 
to people > 45, with the highest rates for those aged >72 [5]. Prescribing rates in older 
people’s nursing homes have been reported to be 40% in Belgium [6], 41%, in England [7], 
and 46% in Sweden [8].  In England and Wales 11.3% of 403,259 people aged > 65 living in 
the community, and 37.5% of 10,387 care home residents, had been prescribed ADs in the 
past 90 days [9]. A study of 271,365 British people found that 28.7% of those with dementia 
3 
 
were on ADs [10]. Of 60,746 British people < 65 diagnosed by their GP as having a new 
episode of depression, 89% were prescribed ADs [11]. 
 
Efficacy and safety of anti-depressants with older people  
Recent research has raised concerns about the efficacy of ADs; with less than half of trials 
finding ADs superior to placebo [12].  A meta-analysis [13] found that ’the overall effect of 
new-generation antidepressant medications is below recommended criteria for clinical 
significance’ (p. 265) with no significant benefit compared to placebo for all but ‘patients at 
the upper end of the very severely depressed category’ (p. 260). A meta-analysis of double-
blind randomized controlled trials with people aged >55 found that SSRIs were not more 
likely to lead to remission than placebos [14].  Two other recent meta-analyses have 
concluded that older age is related to poorer response to ADs [15, 16].  This has been 
partially confirmed with the sample of nearly 2,000 AD users on which the current study is 
based; older people were equally likely as younger people to report improved quality of life 
as a result of taking ADs, but were significantly less likely to report depression reduction 
[17].  
 
The most frequently reported adverse effects in the sample of AD recipients on which the 
current study was based included:  sexual difficulties (62%), feeling emotionally numb 
(60%), drowsiness (58%), dry mouth (58%), weight gain (56%), withdrawal effects (55%); 
feeling not like myself (52%), reduction in positive feelings (42%), suicidality (39%) and 
caring less about others (39%) [18]. Adverse effects that are particularly common amongst 
older people include ischemic stroke, falling, fainting, hip fractures, and acute angle-failure 
glaucoma [6, 11, 19-20].  In the recent study of 60,746 depressed GP patients aged >65 all 
classes of antidepressant drug were significantly associated with: ‘all cause mortality’, 
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attempted suicide/self harm, and upper gastrointestinal bleeding. In addition, SSRIs were 
associated with: stroke/transient ischaemic attack, epilepsy/seizures, and increased risks of 
myocardial infarction and hyponatraemia (low blood sodium level) [11]. Old age can alter the 
pharmacokinetics and pharmacodynamics of ADs, which can affect both efficacy and safety 
of the drugs.  For example, older people are particularly vulnerable to the anticholinergic 
effects of some SSRI agents and thereby to cognitive impairment [21]. In nursing homes 
ADS have been identified as among the most common inappropriately prescribed drugs that 
increase the risk of hospitalisation and death [22].  
 
Objectives of the study 
Given increased prescribing, minimal efficacy, and frequency of adverse effects in older 
people, this study examined: [A] whether older people are prescribed ADs at (i) lower levels 
of depression, (ii) with fewer depressive symptoms, or (iii) without meeting DSM-IV 
diagnostic criteria (i.e. five or more symptoms without significant loss in past two months); 
and [B] whether older people are disproportionately  ‘chronic’ users (defined here as three 
years or more and ongoing). Relevant beliefs, about depression and ADs, which might help 
explain the study’s findings, were also analysed. 
 
Methods 
The study was approved by the University of Auckland Ethics Committee. An anonymous 
questionnaire was placed online and a google webpage advertising the study was established 
[www.viewsonantidepressants.co.nz] [17, 18].  This webpage provided participant 
information and a link to the questionnaire.   The study was further publicised in the media.  
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Instrument 
The questionnaire had 47 questions (in yes/no, likert scale, or open-ended formats), in eight 
sections: demographics; the prescribing process; information about AD usage and perceptions 
of their effectiveness; side-effects; benefits; experiences of alternative treatment options; and 
beliefs about the causes of depression [17, 18].  To ascertain appropriateness of the 
prescription in relation to diagnostic criteria, participants were asked to respond to a checklist 
of symptoms based on the DSM-IV symptoms for Major Depressive Episode (of which five 
are required).  Participants were also asked: “Please rate your level of depression for the year 
before taking antidepressants (‘not at all’, ‘mild’, ‘moderate’ or ‘severe)”, and (to assess for 
the DSM grief exclusion criterion) “In the two months before you were first prescribed 
antidepressants, had a loved one died?” The other two key questions were about how long the 
participants had taken ADs, and whether they were still taking them. 
 
Data Analysis 
Relationships between age and depression severity were analysed using Spearman’s rank 
correlation coefficients, as was the relationship with the 20 adverse effects (but the 
significance level for the latter was, because of the large number of analyses,  set at p < .01. 
to reduce the probability of Type 1 – false positive – errors).  The relationship between age 
and ‘chronic’ usage (taking ADs for three or more years and still taking them) was analysed 
using a chi-square test. For the purposes of further analyses the sample was divided into three 
age groups (‘Younger’: 18-35, n = 690; ‘Middle’: 36-55, n = 846; and ‘Older’: >56, n = 289). 
 
Results 
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Participants 
The criteria for participation included having been prescribed ADs in the last five years and 
being at least 18 years old. Of the 2,171 people who started the survey, 295 stopped before 
question 19 (of 47) and their responses were not analyzed. Of the remaining 1,876, 45 cited 
medications other than ADs when asked which AD they were prescribed.  The Internet 
Protocol address (IP) of 168 of the remaining 1,831, was the same as at least one other 
respondent, indicating possible use of the same computer. The responses of these 168 were 
checked and two respondents whose scores were nearly identical to those of someone else 
with the same IP were excluded. This left 1,829. A further four did not disclose their age and 
were excluded, leaving 1,825 for analysis. Of these, 1399 (76.7%) were female. The majority 
(1,671; 91.6%) were European and 52 (5.3%) Maori. Age groupings ranged from 18-25 years 
(297; 16.3%) to 86+ (2), with the modal grouping being 36-45 (405; 22.1%). 
 
Symptoms, diagnostic criteria and depression severity 
The mean number of DSM symptoms of depression at the time of first being prescribed 
antidepressants, for all respondents, was 6.65 (SD = 2.80). Age was negatively correlated 
with the number of symptoms (r = -0.17; p < .0001). Table 1 shows that the Older group had 
a significantly lower mean number of symptoms (5.68) compared to both the Middle (6.57; t 
= 4.7, df = 1133, p < .0001) and Younger (7.16; t = 4.3, df = 977, p < .0001) groups. Age was 
negatively related to most specific symptoms at the < .0001 level of significance, including 
both of the two symptoms that must be present in DSM 5, depressed mood and reduced 
interest/pleasure, as well as having thoughts of death or suicide (see Table 1).  
 
There were small, but non-significant, differences in the percentage who responded  
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yes to ‘in the two months before you were first prescribed antidepressants, had a loved one 
died?’: Older 9.7%; Middle 7.2%; Younger  6.4%. 
 
Older age was negatively related to probability of meeting DSM diagnostic criteria (X2 =37.7; 
p < .0001); with only 59.4% of the Older group reporting five DSM symptoms (and no loss 
of loved one)  at the time of first being prescribed DS, compared to 74.0% and 78.3% for the 
Middle and Younger groups respectively.  
 
Men, in general, had significantly fewer symptoms (6.32) than women (6.76) (t = 2.85, df = 
666, p < .01). An Analysis of Variance, with age and gender as predictors and number of 
symptoms as the dependent variable, found that age was significantly predictive (t = 7.28, p < 
.0001) and gender was not quite predictive (t = 1.96; p = .05). The difference between 
genders in the percentages that met DSM criteria (men 70.1%; women 74.3%) was not 
statistically significant.  
 
Age was negatively, but not significantly, related to self-reported severity of depression in 
‘the year before taking antidepressants’ (r = - .04, p = .08). The difference between 38.7% of 
the Older group reporting ‘severe’ depression, and 44.2% of the Younger group, was not 
significant.  
 
Chronic usage 
About half of the sample (51.7%) had taken ADs for three years or more. This was positively 
related to age (X2 = 74.7; p < .0001). About two thirds (65.7%) of the Older group, but only 
38.9% of the Younger group had taken ADs for three years or more. 
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Age was positively related to still taking ADs at the time of completing the survey (X2 = 27.2, 
p < .0001). This was the case for 74.2% of the Older group and 66.0% of the Younger group. 
 
Age was, therefore, strongly related to having taken ADs for three years and still taking them, 
combined (the operational definition of ‘chronic usage’ for the purpose of this study) (X2 = 
84.3, p < .0001). This was the case for 59.0% of the Older group, 46.9% of the Middle group 
and 33.5% of the Younger group. There was no gender differences in terms of chronic 
useage. 
 
Withdrawal and other adverse effects 
Age was not significantly related to self-reported ‘addiction’ or ‘withdrawal effects’. About a 
quarter of the Older respondents (27%) reported experiencing some degree of addiction; with 
6% saying that the level of addiction was ‘severe’.  Nearly half (48%) had experienced 
‘Withdrawal effects after stopping taking the anti-depressants’ with one in five (22%) 
describing them as ‘severe’.  
 
Although age was negatively correlated to the total number of adverse effects [18], more than 
40% of the older group reported seven other adverse effects besides withdrawal effects: Dry 
mouth (60%); Sexual difficulties (58%), Weight gain (58%); Feeling emotionally numb 
(55%); Failure to reach orgasm (54%); Drowsiness (50%); and Feeling not like myself 
(43%). In addition, 36% reported Reduction in positive feelings; 35% Caring less about 
others; and 29% Suicidality. 
 
Interaction with Prescriber 
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Age was unrelated to whether the prescriber told the patient how long to take the ADs and, if 
they were told, how long they were told to take them.  
 
Beliefs 
Participants were asked about the extent to which they agreed with a range of causes, of 
depression in general [23] and of their own depression [24]. Age was unrelated to belief in 
‘Chemical Imbalance’ as a cause of either. However, age was negatively related to a belief in 
‘Disorder of the brain’ as a cause of either depression in general or of their own depression. 
Over half of the Older group (57.9%) disagreed with ‘Disorder of the brain’ as a cause of 
their own depression, compared to 48.3% of the Middle group, and 34.2% of the Younger 
group. 
 
Participants were asked to respond to: ‘If you benefited from antidepressants, to what extent 
to you think it was because of the chemical effect of the antidepressants vs. the placebo 
effects of hope and expectation’ by ticking one of ten boxes ranging from ‘100% chemical  to 
‘100% placebo’ [23].  Age was negatively related to degree of belief in placebo effects (r = -
.21, p < .0001); with 40.1% of the Older group believing that the effect of ADs was 100% 
chemical, compared to 31.0% of the Middle group and only 20.2% of the Younger group.  
 
Discussion 
A recent study found that 69% of AD recipients in Baltimore had never met DSM criteria for 
Major Depressive Disorder and concluded that ‘Our data indicate that antidepressants are 
commonly used in the absence of clear evidence-based indications’ [25, p. 40]. The current 
study suggests that this may disproportionately be the case for older people. In the current 
sample, the largest online survey of AD recipients to date, people over 55 were prescribed 
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ADs with fewer DSM symptoms of depression. They were more likely to be prescribed ADs 
without meeting DSM criteria for a Major Depressive Episode. They did not report being 
significantly more or less depressed than younger people in the year prior to being prescribed 
ADs, but they were significantly less likely to report having the symptom ‘down or 
depressed’ at the time of the prescription. This first group of findings is consistent with the 
previous finding that older people are more likely than younger people to be prescribed ADs 
in the absence of a diagnosis [26].  For example, 33% of Swedish nursing home residents 
without a diagnosis of depression were found to be taking ADs [8].  A study of Canadian 
medical inpatients aged > 65 found that in the subsequent six months those with no 
depression were prescribed SSRIs at the same rate as those with minor depression [21]. 
Among residents of three Sydney nursing homes 27% of those with no significant symptoms 
of depression were on antidepressants, at a similar rate (23%) to those with a moderate level 
of symptoms [27]. A study of US Veterans found that of the just over half a million 
prescribed ADs outside of mental health services in 2010, 51% had no psychiatric diagnosis; 
and that Veterans aged 65 or older were more than four times more likely than those under 40 
to be prescribed psychiatric drugs without a diagnosis [28]. These findings of high rates of 
apparently inappropriate prescribing occur in the context of t older people having a lower 
prevalence of depression, with shorter duration and less severity [2]. 
The other major finding of the current study was that people over 55 are more likely to be 
‘chronic’ users of ADs, and thereby may be disproportionately contributing to the ever 
increasing prescribing rates of ADs internationally.  These two primary findings cannot be 
explained either by specific instructions from prescribers about how long to take the 
medication or by older participants having a more biological understanding of depression. 
However, older people in the current sample believed more strongly than the younger people 
that ADs are ‘the best treatment’ and that their effect is more chemical than placebo [23]. 
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These two beliefs may partially explain their longer use of the drugs, and even - via pressure 
on the prescriber -  why they are given them without meeting diagnostic criteria. The 
additional finding that the older people reported fewer adverse effects [18] may be a further 
partial explanation for the longer duration of use. 
 
The findings should be considered in conjunction with the additional finding, from the same 
survey, that older people received significantly fewer other (non-medical) treatment 
recommendations at the time of AD prescription, and were specifically less likely to have  
‘Counsellor/Psychologist/Psychotherapist’ or ‘Social Activities’ suggested to them. 
 
A recent analysis of Australian national data found that people over 65 were frequently 
prescribed potentially inappropriate medicines, and  ‘that health practitioners indicated that 
they do not routinely elicit patient preferences or initiate conversations about the risks and 
benefits of medicines’ [29, p.35]  
 
Limitations 
The study used a convenience sample which was not demographically representative of the 
New Zealand general population. Self-reports are subject to the failings of memory. 
Correlations are not necessarily indicative of a causal relationship between variables. 
It is not clear how many of the participants were still depressed when completing the 
questionnaire.  
 
The definition of ‘older’ (>56) was lower than many other studies, but no signifcant 
differences were found between the 56-65 and >65 groups on the key variables. For example, 
the mean number of symptoms was 5.7 for the 56-65 year olds and 5.5 for those over 65. 
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Older people may more often be prescribed ADs for issues other than depression (e.g. post 
stroke); but there were no significant differences between the three age groups in the 
percentage who reported that they were ‘not at all’ depressed in the year prior to first being 
prescribed ADs. 
Conclusions 
Many older people, including the majority of the current sample (82%), find ADs beneficial. 
Most, however, also experience multiple adverse effects. Nearly half of the current sample of 
older people had tried to reduce or come off but had experienced withdrawal effects, which 
one in five described as ‘severe’.  
 
Similar surveys of the attitudes and beliefs of prescribers, and in relation to other psychiatric 
drugs, may prove valuable. In the meantime, prescribers might consider alternatives to ADs, 
including exercise, social activity and psychological therapies such as cognitive therapy [30], 
or even a ‘wait and see’ approach, especially for moderate to mild depression (the majority of 
AD users). In relation to older people, doctors should be particularly focussed on ensuring (a) 
that ADs are not being prescribed unnecessarily (ie in the absence of depression), (b) that the 
advantages and disadvantages of ADs are discussed, (c) that other treatments are considered, 
including those that address psycho-social needs such as loneliness, (d) that interactions with 
other drugs are carefully monitored and (e) that chronic use is monitored and, where possible, 
avoided.  
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Key Points 
 People over 55 are prescribed antidepressants on the basis of fewer depressive symptoms ,  
and lower probability of meeting  DSM criteria for Major Depressive Episode, than younger 
people.  
 People over 55 are more likely to be chronic users of antidepressants. 
 Prescribers should discuss the pros and cons of, and alternatives to, antidepressants with older 
patients, and avoid unnecessary or chronic prescribing. 
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Table 1: Symptoms, level of depression and chronic usage, by age 
                                                        18‐35 years     36‐55 years       >55 years 
                                                           (n = 690)         (n = 846)            (n = 289) 
 depressed mood                            90.6%               86.9%                  79.9% * 
diminished interest/pleasure       78.6%               76.8%                 66.1% * 
thoughts of death/suicide’           62.5%               52.1%                  44.3% * 
Mean number of symptoms         7.16                  6.57                     5.68 * 
Met DSM criteria 1                          78.3%              74.0%                  59.4% * 
‘severe’ depression in year           44.2%              42.9%                  38.7%  ns 
 prior to starting ADs 
 
Chronic usage 2                               33.5%                   46.9%               59.0% * 
1 =  five DSM symptoms and no loss of loved one in previous two months 
2 =  taken ADs for three years and still taking them;    * = p < .0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
